Patients with AML who carried NPM1 gene mutations in the absence of FLT3-ITD mutations were classified into a favorable prognosis group [21] that is susceptible to chemotherapy as compared to patients with AML without NPM1 mutations and showed the best complete remission rate among these patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.